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Elevated circulating concentrations of low-density lipoproteins have been definitively demonstrated
to be a cause of atherosclerotic cardiovascular disease (ASCVD). Increasing recognition is given to
the importance of reducing lifetime exposure to low-density lipoprotein cholesterol (LDL-C)1
according to the rule of “the lower the better,” but also “the earlier the better” and “the longer the
better.” Statin therapy reduces the risk of cardiovascular events by approximately a quarter for each
reduction in low-density lipoprotein level of 38.6 mg/dL (1 mmol), and long-term LDL-C reduction
(40 years) might even be associated with a reduction of cardiovascular mortality by 50% to 55%. The
largest absolute benefits of statin therapy occur in individuals at the greatest risk, such as those who
have already experienced an ASCVD event.2 Taken together, these facts might lead us to expect near-
universal coverage of statin therapy in the secondary prevention of ASCVD. However, Yao and
colleagues3 shed light on how and why this is not the case in an actual setting. Their 10-year
retrospective cohort study using administrative data from 2007-2016 in the US demonstrated
increases in the proportion of secondary prevention patients receiving statins (50.3% to 59.9%) and
high-intensity statins (25.0% to 49.2%) during the study period. The proportion of patients adherent
to statin therapy also increased, from 58.7% to 70.5%.
It is clear that these trends are all in the right direction, but there is still a very long way to go to
obtain the maximum possible health benefits from lipid-lowering therapy. It is especially true after
the publication of the European Society of Cardiology/European Atherosclerosis Society 2019 lipid
guidelines, which decreased the LDL-C target to less than 55 mg/dL (1.4 mmol/L) for very high-risk
patients, and which defined patients with extremely high cardiovascular disease risk as those with a
second vascular event within 2 years while receiving maximally tolerated statin therapy, and
recommended an LDL-C goal of less than 40 mg/dL (1 mmol/L).4 This target is unlikely to be achieved
without good adherence to maximally tolerated statin therapy, and recent data suggest that the goal
of less than 55 mg/dL (1.4 mmol/L) is achieved in only 18% of patients.5 Thus, to meet these targets,
experts have recently proposed initial combination therapy with statins and ezetimibe, or triple
therapy with proprotein convertase subtilisin/kexin type 9 inhibitors, especially for patients with
high baseline LDL-C levels (in which the predicted extent of LDL-C reduction with statins is unlikely
to reach the target) and for those at extreme cardiovascular disease risk with the precise definition of
this risk group.4,6,7
Of particular concern was the finding by Yao and colleagues3 that women and ethnic minorities
were less likely to receive and adhere to statins. The reasons for these discrepancies need to be
explored and addressed as a matter of priority. Cost is probably not a major contributor to these
differences. The study included only privately insured and Medicare Advantage patients, which limits
the eternal validity of the work but reduces the potential for confounding by expense.3 In any event,
the availability of generic statins led to reductions in the cost of statin therapy during the course of
the study, which were far more significant than the corresponding increase in statin use. The same
phenomenon has been noted with generic ezetimibe; despite that the cost decreased substantially 3
years ago, it is used by only 15% to 20% of patients with indications for combination therapy.
Could different susceptibilities to statin nonadherence/intolerance explain the differences in the
extent of statin use? This question cannot easily be answered from an administrative data set; however,
it is clear that further research is needed to determine the risk factors for statin intolerance and how
these can be addressed. Yao and colleagues3 used an algorithm that identified statin intolerance from
down-titration or discontinuation of therapy, use of multiple statins, or a diagnosis of adverse effects.
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This approach is the most rigorous possible in a retrospective study, but it cannot precisely match clini-
cal definitions of statin intolerance,8 nor can it be certain to distinguish true intolerance from the
“drucebo” effect (whereby symptoms are attributed to statin therapy even when the link is not causal,
such as muscle pain resulting from musculoskeletal injury).9 Identification and careful management of
these patients will enable them to benefit from statin therapy, especially because it has been confirmed
that as many as 95% of patients reporting muscle pain after statin therapy can still receive statins, and
complete statin intolerance is observed in no more than 3 to 5 patients per 100.
A particular strength of this research is the wide-ranging definition of ASCVD used. Use of such
a large data set (284 949 patients) allows a broader approach to inclusion criteria than is often
achievable in randomized controlled trials.3 The study included patients with myocardial infarction,
angina, revascularization, ischemic stroke, and transient ischemic attack. However, the largest group
of participants (composing > 40% of the study population) was patients with peripheral artery
disease.3 This inclusion is important because of observations that patients with peripheral artery
disease (PAD) (and polyvascular disease) have a high risk of cardiovascular and all-cause mortality,
and that the risk of stroke or myocardial infarction in patients with PAD is equivalent to that of those
with coronary disease. Statin use, high-intensity statin use, and statin adherence were all lower in
patients with stroke, transient ischemic attack, and PAD than in those with coronary artery disease.
This is of particular interest because, according to the recent definition, patients with early acute
coronary syndrome with PAD/ or polyvascular disease and not reaching the LDL-C goal despite
optimal lipid-lowering therapy are classified as having extremely high cardiovascular risk.7 Yao et al3
discussed the possibility that this finding may result from a misperception that patients without
coronary heart disease are at lower risk of subsequent ASCVD events, and the fact that most large
statin trials recruited a population of coronary heart disease patients. Whatever the reason, this
finding illustrates a key area in which statin use might be improved by patient education and clear
guidelines for physicians.
The period during which this study was conducted is interesting and might represent the end of
the era in which the burden of lipid-lowering therapy in ASCVD was largely on statins alone.
Ezetimibe was available during the course of the study (and it would have been interesting to have
more data on add-on therapies such as ezetimibe and nutraceuticals) and newer lipid-lowering
agents are increasingly available. As such, were this study to be repeated in a further 10 years, the
focus on statins without consideration of other drugs would give an incomplete representation of
ASCVD risk reduction. Meanwhile, this study demonstrates the enormous potential benefit of more
widespread use of statins—and the challenge in achieving that benefit. This study might also
convince physicians that in the case of statin nonadherence, intolerance, or both, we should not wait
weeks or even months in trying to achieve maximally tolerated statin doses. Instead, we should
immediately start combination therapy with ezetimibe, proprotein convertase subtilisin/kexin type
9 inhibitors, and even nutraceuticals to avoid visit-to-visit variability in LDL-C levels and the
consequent increased risk of recurrent cardiovascular disease, especially in patients at very high and
extreme risk of cardiovascular disease.
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